幽门螺旋杆菌与胃外疾病相关性研究进展

Lansoprazole based quadruple therapy for treatment of patients with Helicobacter pylori associated gastric ulcer: Efficacy and impact on serum levels of interferon-γ, interleukin-2, and interleukin-12

AIM

To evaluate the clinical effects of lansoprazole based quadruple therapy in patients with Helicobacter pylori (H. pylori) associated gastric ulcer and the impact on serum levels of interferon-γ (IFN-γ), interleukin (IL)-2, and IL-12.

METHODS

One hundred and twenty cases treated from June 2016 to June 2017 at Hangzhou Hospital were randomly divided into a control group (n = 60) and an observation group (n = 60). The control group was given omeprazole based quadruple therapy, while the observation group was given lansoprazole based quadruple therapy. After treatment for 1 month, the total effective rate, H. pylori eradication rate, time to relief of symptoms, serum levels of IFN-γ, IL-2, and IL-12, levels of superoxide dismutase (SOD), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF), and adverse reactions in the two groups were observed. After follow-up for 6 mo, the rates of relapse in patients with H. pylori eradication and those with response to therapy were observed.

RESULTS

The total effective rate and H. pylori eradication rate were significantly better in the observation group than in the control group (100% vs 88.3%, 85.0% vs 96.7% P < 0.05 for both). The time to relief of abdominal pain, bloating, belching, and bleeding was significantly shorter in the observation group than in the control group (P < 0.05). After treatment, serum levels of IFN-γ, IL-2, and IL-12 in both groups were significantly lower than those before treatment (P < 0.05), and the observation group had significantly lower levels than the control group (P < 0.05); the levels of SOD, VEGF, and EGF were significantly improved in both groups compared with the values before treatment (P < 0.05), and the observation group had significantly better levels than the control group (P < 0.05). After follow-up for 6 mo, the relapse rates in patients with H. pylori eradication of the two groups were 17.65% and 3.44%, and the relapse rates in those with response to therapy were 15.09% and 3.33%; the observation group was significantly better than the control group (P < 0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05).

CONCLUSION

Lansoprazole based quadruple therapy for treatment of patients with H. pylori associated gastric ulcer is significantly effective and can reduce the levels of inflammatory factors, promote gastric mucosal repair, and reduce relapse.